Sponsor Check › Person
Related person on Form D filings · address state as listed: CA · listed Apr 12, 2010 → Sep 15, 2025
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 22 offerings report sales commissions totalling $5,625,555; 0 report finder's fees; 1 reports proceeds to related persons totalling $350,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Sep 15, 2025 D File 021-557520 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 1, 2025 D File 021-544914 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 5, 2023 D File 021-483338 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 8, 2021 D File 021-395148 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2020 D File 021-370879 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 11, 2020 D/A File 021-323159 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 5, 2019 D File 021-348039 | $3,625,555 (est.) | $0 | $0 | BFC Group Ltd. no CRD number reported Cowen and Company, LLC BrokerCheck CRD 7616 ↗ |
| EDGAR ↗ | Nov 21, 2018 D File 021-326302 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 30, 2018 D File 021-318040 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 26, 2018 D File 021-306354 | $0 | $0 | $350,000 | None listed on this filing |
| EDGAR ↗ | Dec 19, 2017 D File 021-301171 | $2,000,000 (est.) | $0 | $0 | PJT Partners LP BrokerCheck CRD 171058 ↗ |
| EDGAR ↗ | Sep 27, 2017 D File 021-295508 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2017 D/A File 021-245323 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 4, 2016 D File 021-260605 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 16, 2016 D/A File 021-248004 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2015 D/A File 021-242928 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 15, 2015 D File 021-240038 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 8, 2013 D/A File 021-201695 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 22, 2013 D File 021-205019 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 28, 2013 D File 021-194099 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 3, 2011 D File 021-163893 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 12, 2010 D/A File 021-105039 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | selectIon, Inc. | Director | Sep 15, 2025 | D | $20,000,022 similar: $2,000,000–$19,999,994 | $5,430,646 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Alessa Therapeutics, Inc. | Executive Officer, Director | May 1, 2025 | D | $31,616,096 similar: $829,831–$9,999,998 | $25,376,457 | 14 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | selectIon, Inc. | Director | Jun 5, 2023 | D | $11,809,601 similar: $2,000,000–$19,999,994 | $5,002,772 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | selectIon, Inc. | Director | Apr 8, 2021 | D | $5,059,996 similar: $2,000,000–$19,999,994 | $5,059,996 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VelosBio Inc. | Director | Jul 14, 2020 | D | $137,000,002 similar: $2,000,000–$19,999,994 | $137,000,002 | 38 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VelosBio Inc. | Director | May 11, 2020 | D/A | $59,305,204 similar: $2,000,000–$19,999,994 | $59,305,204 | 38 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zeno Pharma, LLC | Executive Officer, Director Secretary of Issuer | Sep 5, 2019 | D | Indefinite similar: $1,694,259–$16,000,000 | $0 | 0 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Oncternal Therapeutics, Inc. group: Oncternal Therapeutics | Director | Nov 21, 2018 | D | $24,000,000 similar: $2,000,000–$19,999,994 | $17,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VelosBio Inc. | Director | Oct 10, 2018 | D | $58,055,204 similar: $2,000,000–$19,999,994 | $35,301,245 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VelosBio Inc. | Director | Jul 30, 2018 | D | $6,480,000 similar: $2,000,000–$19,999,994 | $6,480,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VelosBio Inc. | Director | Feb 26, 2018 | D | $7,700,000 similar: $2,000,000–$19,999,994 | $7,700,000 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zeno Pharma, LLC | Executive Officer, Director Secretary of Issuer | Dec 19, 2017 | D | Indefinite similar: $1,694,259–$16,000,000 | $0 | 0 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Oncternal Therapeutics, Inc. group: Oncternal Therapeutics | Director | Sep 27, 2017 | D | $11,251,125 similar: $2,000,000–$19,999,994 | $6,850,397 | 121 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oncternal Therapeutics, Inc. group: Oncternal Therapeutics | Director | Mar 23, 2017 | D/A | $23,504,838 similar: $2,000,000–$19,999,994 | $17,874,045 | 111 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oncternal Therapeutics, Inc. group: Oncternal Therapeutics | Director | Dec 9, 2016 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $11,281,734 | 95 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oncternal Therapeutics, Inc. group: Oncternal Therapeutics | Director | Oct 20, 2016 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $6,083,738 | 72 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zavante Therapeutics, Inc. | Executive Officer Chief Business Officer | Apr 4, 2016 | D | $45,731,764 similar: $1,694,259–$16,000,000 | $45,731,764 | 54 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zeno Pharmaceuticals, Inc. | Executive Officer, Director | Mar 16, 2016 | D/A | $18,319,984 similar: $1,694,259–$16,000,000 | $18,319,984 | 11 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zavante Therapeutics, Inc. | Executive Officer Secretary | Dec 22, 2015 | D/A | Indefinite similar: $1,694,259–$16,000,000 | $10,283,486 | 48 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zeno Pharmaceuticals, Inc. | Executive Officer, Director | Sep 22, 2015 | D | $18,000,006 similar: $1,694,259–$16,000,000 | $15,000,006 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zavante Therapeutics, Inc. | Executive Officer Secretary | Jul 1, 2015 | D | $4,184,863 similar: $1,694,259–$16,000,000 | $4,184,863 | 28 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zavante Therapeutics, Inc. | Executive Officer Secretary | May 15, 2015 | D | $14,200 similar: $1,694,259–$16,000,000 | $14,200 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Kalyra Pharmaceuticals, Inc. | Executive Officer | Nov 8, 2013 | D/A | $7,000,000 similar: $2,000,000–$19,999,994 | $6,181,380 | 32 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Sorrento Therapeutics, Inc. group: Sorrento Therapeutics | Director | Oct 22, 2013 | D | $1,850,000 similar: $2,000,000–$19,999,994 | $1,850,000 | 9 similar: 2–16 | $100 similar: $10,000–$50,000 |
| EDGAR ↗ | Kalyra Pharmaceuticals, Inc. | Executive Officer | Aug 21, 2013 | D | $6,000,000 similar: $2,000,000–$19,999,994 | $5,172,879 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Sorrento Therapeutics, Inc. group: Sorrento Therapeutics | Director | Mar 28, 2013 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $6,418,495 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NERVEDA LLC | Executive Officer, Director, Promoter | Aug 3, 2011 | D | $7,779,020 similar: $2,000,000–$19,999,994 | $3,899,510 | 36 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NERVEDA LLC | Executive Officer, Director, Promoter | Apr 12, 2010 | D/A | $27,000,000 similar: $2,000,000–$19,999,994 | $14,135,454 | 55 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Other Health Care / 506(b) (4,189 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Cam Gallagher. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Cam Gallagher appears on a new Form D, or when a court case or SEC action is matched to them. See plans →